The Ethics of Characterizing Difference: Guiding Principles on Using Racial
Categories in Human Genetics
By Sandra Soo-Jin Lee et. al.,
Genome Biology
| 07. 15. 2008
Abstract
We are a multidisciplinary group of Stanford faculty who propose ten principles to guide the use of racial and ethnic categories when characterizing group differences in research into human genetic variation.
Open letter
Since the completion of the Human Genome Project, research focused on human genetic variation, including differences among groups, has intensified. This focus has rekindled debates about the connection between genetic (DNA-level) traits and human 'racial' difference [1-5]. Scholars are divided on the question of whether racial categorization is an appropriate means of organizing potentially useful genetic data or a pernicious reification of historically destructive typologies [6,7]. To explore these issues, faculty from the humanities, social sciences, life sciences, law and medicine at Stanford University convened over the past few years to engage in an extended interdisciplinary dialog. The initial meeting consisted of a two-day workshop in 2003 that developed into an ongoing faculty research seminar sponsored by the Stanford Humanities Center, Affymetrix Corporation, the Mellon Foundation and the Research Institute of the Center for Comparative Studies on Race and Ethnicity. This seminar series, which continued for...
Related Articles
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
By Carolyn Riley Chapman and Nirvan Bhatia, Hastings Bioethics Forum | 03.12.2026
Last year, researchers saved an infant named KJ from a life-threatening rare metabolic disorder using a customized gene editing therapy. This was the first time that an individualized gene therapy was used to treat a human patient, and it has...